New pill and immunotherapy combo tested for Hard-to-Treat cancers
NCT ID NCT06082960
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handles the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GS-9911 (oral tablet) and zimberelimab (intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, 06520, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, M5G, Canada